Market News & Trends
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
AdrenoMed AG recently announced the US FDA granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment…
Palisade Bio Presents Development Overview for Moderate-to-Severe Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it presented at IBD Innovate: Product Development for Crohn’s & Colitis held April 9-10, 2024, in Cambridge, MA. As part…
IO Biotech Presents New Data Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine
IO Biotech recently shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the 2004 American Association for Cancer Research (AACR)…
NeuroSense Collaborates With Lonza to Identify Exosome-Based Biomarkers to Advance Neurodegenerative Disease Treatments & Diagnostics
Lonza and NeuroSense Therapeutics Ltd. recently announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS. This agreement provides NeuroSense…
Essential Pharma Acquires Renaissance Pharma With its Clinical-Stage Immunotherapy
Essential Pharma recently announced it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance Pharma is a clinical-stage pharmaceutical…
INmune Bio Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer
INmune Bio, Inc. recently presented data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment…
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases
MiNK Therapeutics, Inc. recently announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the…
AustinPx Invests in Pharmaceutics & Manufacturing Capabilities to Accelerate Drug Development
AustinPx recently announced its acquisition of a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer, and the STYL’One Nano compaction simulator. The…
Ocugen Announces FDA Clearance of IND Amendment to Initiate Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 With a Broad Retinitis Pigmentosa Indication
Ocugen, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400,…
Bio-Rad & Allegheny Health Network Cancer Institute Collaborate to Advance Personalized Monitoring of Solid Tumor Cancers With Droplet Digital PCR
Bio-Rad Laboratories, Inc. recently announced a collaboration with Allegheny Health Network (AHN) aimed to generate clinical evidence across a range of cancer types to support…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….